Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study.
Ya ChenYanan WangZhengyu YangMinjuan HuJun LuYanwei ZhangFangfei QianBo ZhangShuyuan WangKai WangWei ZhangBao-Hui HanPublished in: Thoracic cancer (2022)
The present study shows that LCT to metastatic sites is an option for consideration in patients with synchronous oligometastatic NSCLC during first-line pembrolizumab treatment, with significantly improved PFS and OS compared with systemic treatment alone.